Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21236263 | 0.86 | APP (0.41) | LMNAALDH1A1 | |
| SCHEMBL26144799 | 0.80 | — | — | |
| SCHEMBL20942663 | 0.78 | CA1 (0.30) | — | |
| SCHEMBL805360 | 0.77 | ACACB (0.37) | CYP2C19 | |
| SCHEMBL12138293 | 0.75 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL20942728 | 0.75 | NLRP3 (0.32) | — | |
| SCHEMBL25932730 | 0.75 | PTGS1 (0.36) | — | |
| SCHEMBL20034868 | 0.75 | CA2 (0.30) | — | |
| SCHEMBL10106473 | 0.73 | HPGD (0.38) | LMNAALDH1A1HPGD | |
| SCHEMBL15672832 | 0.73 | GRIA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | ORCHID PHARMA LTD. (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20210047281-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC. (CN) | 2021-02-18 | — | — | US | disclosed |
| WO-2019149255-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都海创药业有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1896465-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | Takeda Cambridge Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | SLC11A2, GSK3B, GSK3A | LMNA 564/4885SLC6A6 3774/4885CYP2C19 113/4885 |
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | IDO1, IDO2, TPH1 | LMNA 3797/4885SLC6A6 2990/4885CYP2C19 52/4885 |
| US-20210047281-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | IDO1, IDO2, TPH1 | LMNA 3797/4885SLC6A6 2990/4885CYP2C19 52/4885 |
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | LMNA 2647/4885SLC6A6 4864/4885CYP2C19 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.